Full-Time

Director – Target Profiling

Translational Research

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Biotechnology
Healthcare

Expert

Cambridge, MA, USA

Expected to be in office 70% of the time with flexibility to work from home up to 30%.

Category
Lab & Research
Medical Research
Requirements
  • Ph.D. in a relevant scientific discipline (e.g., oncology, immunology, cancer biology, immune-oncology) with a minimum of 10 years of experience in translational research within the pharmaceutical or biotechnology industry, preferably in immune-oncology or autoimmune therapeutic areas.
  • Proven expertise in developing and validating CDx assays and disease monitoring tools.
  • Strong background in developing flow cytometry, ctDNA sequencing, MRD methodologies, and protein-based assays to inform clinical development.
  • Excellent communication and collaboration skills, with experience working in cross-functional teams.
  • A results-driven mindset, capable of thriving in a fast-paced, innovative environment.
  • A passion for advancing precision medicine to improve outcomes for patients.
  • Demonstrated ability to innovate translational approaches for novel therapeutic concepts or modalities.
  • Experience with regulatory submissions and interactions with health authorities is highly desirable.
  • Demonstrated success in developing and integrating companion diagnostics into therapeutic development strategies.
  • Excellent project management and organizational skills, with the ability to manage multiple cancer vaccine projects simultaneously.
  • Strong leadership and interpersonal skills, with the ability to influence and lead cross-functional teams.
  • Demonstrated proficiency in effectively managing and developing direct reports.
  • Exceptional communication skills, both written and verbal, with the ability to effectively convey complex scientific information related to cancer vaccines to a variety of audiences.
  • A strong publication record in peer-reviewed journals is preferred, particularly in the field of cancer immunotherapy or autoimmunity.
Responsibilities
  • Develop and validate cutting-edge methodologies, including ctDNA, MRD, and protein-based assays, to monitor disease progression and therapeutic efficacy in a variety of clinical settings and disease indications.
  • Lead the development of stage-appropriate CDx assays to enable precision patient profiling and inform strategies for therapeutic intervention.
  • Manage the implementation of flow cytometry and other advanced profiling techniques to characterize and/or stratify patient populations effectively.
  • Collaborate with Preclinical Program teams, Translational Medicine and Clinical Biomarker teams to define and implement comprehensive translational strategies to drive programs from concept to clinic.
  • Stay at the forefront of scientific and technological advancements in precision targeting and companion diagnostics.
  • Contribute to the broader translational research team strategy, fostering innovation and excellence.
  • Oversee relationships with CROs and internal labs to ensure the timely completion of assay development, qualification, and validation studies, delivering high-quality data for translational research projects.
  • Mentor and develop junior scientists within the translational research team, fostering a culture of scientific excellence and continuous learning.
  • Act as a scientific liaison and thought partner for key internal and external collaborators, including development and regulatory colleagues, academic institutions, and industry collaborators in the oncology space.
  • Contribute to the preparation of regulatory submissions, scientific publications, and presentations, effectively communicating translational research outcomes.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in the process of protein synthesis in cells. Their approach involves creating mRNA-based therapies that instruct cells to produce proteins that can help treat diseases. This method allows for a more flexible and efficient way to develop and manufacture medicines compared to traditional methods. What sets Moderna apart from its competitors is its exclusive focus on mRNA technology, which has the potential to create a new category of treatments. The company's goal is to harness the power of mRNA to significantly improve patient outcomes and transform the landscape of medicine.

Company Stage

IPO

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

2010

Growth & Insights
Headcount

6 month growth

4%

1 year growth

16%

2 year growth

55%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's Melbourne facility accelerates vaccine production by bypassing regulatory hurdles.
  • Collaboration with OpenAI enhances drug discovery efficiency using AI.
  • Participation in major investor conferences attracts new investors and partnerships.

What critics are saying

  • Potential removal from Nasdaq 100 could affect investor perception and stock liquidity.
  • Bypassing safety steps in Australia may raise regulatory and public safety concerns.
  • Hong Kong's reluctance to vaccinate indicates challenges in market acceptance.

What makes Moderna unique

  • Moderna is pioneering mRNA technology for a new class of medicines.
  • The company has developed one of the earliest and most effective COVID-19 vaccines.
  • Moderna's mRNA platform targets infectious diseases, immuno-oncology, and rare diseases.

Help us improve and share your feedback! Did you find this helpful?